ESC Guidelines on Heart Failure
... An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA Class II–III), and an LVEF ≤35% despite ≥3 months of OMT, provided they are expected to survive substantially longer than one year with good functional status, and they have: • IHD ...
... An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA Class II–III), and an LVEF ≤35% despite ≥3 months of OMT, provided they are expected to survive substantially longer than one year with good functional status, and they have: • IHD ...
Full Text - Diabetes Care
... of power in this study remains possible. The metabolic/myocardial fuel-supply hypothesis postulates that empagliflozin, through increased ketone body production such as b-hydroxybutarate, may provide an alternative and potentially more efficient source of myocardial adenosine triphosphate (5). Changes ...
... of power in this study remains possible. The metabolic/myocardial fuel-supply hypothesis postulates that empagliflozin, through increased ketone body production such as b-hydroxybutarate, may provide an alternative and potentially more efficient source of myocardial adenosine triphosphate (5). Changes ...
View Abstract
... Patients with SCD had significantly higher mean±SD values for tricuspid regurgitant jet velocity than did the controls (2.1±0.6 vs. 1.8±0.5; p<0.001). 25% of SCD patients had elevated systolic pulmonary artery pressure (PAP) as defined by jet velocity ≥2.5 m/s(estimated systolic PAP ≥30 mm Hg) compa ...
... Patients with SCD had significantly higher mean±SD values for tricuspid regurgitant jet velocity than did the controls (2.1±0.6 vs. 1.8±0.5; p<0.001). 25% of SCD patients had elevated systolic pulmonary artery pressure (PAP) as defined by jet velocity ≥2.5 m/s(estimated systolic PAP ≥30 mm Hg) compa ...
ADAM Interactive Physiology
... heart would look like if you took a photo of it at each of the labeled points (A, B, C, D) on the ECG (EKG) below. You are drawing contraction, not electrical messages. A helpful resource aside from ADAM is the website I showed in class: http://library.med.utah.edu/kw/pharm/hyper_heart1.html. There ...
... heart would look like if you took a photo of it at each of the labeled points (A, B, C, D) on the ECG (EKG) below. You are drawing contraction, not electrical messages. A helpful resource aside from ADAM is the website I showed in class: http://library.med.utah.edu/kw/pharm/hyper_heart1.html. There ...
Doc - Medtronic
... Persistent AF occurs when the heart’s upper chambers beat erratically for more than seven days and medical intervention or drug therapy is needed to stop the episode. Permanent or continuous AF occurs when the heart’s upper chambers consistently beat erratically at very high rates. This is the m ...
... Persistent AF occurs when the heart’s upper chambers beat erratically for more than seven days and medical intervention or drug therapy is needed to stop the episode. Permanent or continuous AF occurs when the heart’s upper chambers consistently beat erratically at very high rates. This is the m ...
Slide 1
... Cardiac sarcoidosis: VT ablation (II) • Multicentre registry, N=42 patients • VT refractory to medical therapy in 9 – Age 47 +/- 9 yrs, LVEF 42 +/- 14% ...
... Cardiac sarcoidosis: VT ablation (II) • Multicentre registry, N=42 patients • VT refractory to medical therapy in 9 – Age 47 +/- 9 yrs, LVEF 42 +/- 14% ...
Automated External Defibrillators (AEDs) Potential areas and targets
... • 140,000 deaths per year in the UK***. * World Health Organization – 2004 Statistics ** American Heart Association *** Meditrain, UK ...
... • 140,000 deaths per year in the UK***. * World Health Organization – 2004 Statistics ** American Heart Association *** Meditrain, UK ...
Chapter 20 I am - Mrs Smith`s Biology
... contracting simultaneously and sending blood down into ventricles through the open AV valves SAN (Sino-Atrial Node) ...
... contracting simultaneously and sending blood down into ventricles through the open AV valves SAN (Sino-Atrial Node) ...
Cardiology.Part2.GNRS5
... • Symptomatic patients with severe chronic MR and LVEF >30% • Asymptomatic patients with severe chronic MR and LVEF 30%–60% and/or left ventricular end-systolic dimension 4 cm • When mitral valve repair is deemed likely to be successful in asymptomatic patients with severe chronic MR and an LVEF 6 ...
... • Symptomatic patients with severe chronic MR and LVEF >30% • Asymptomatic patients with severe chronic MR and LVEF 30%–60% and/or left ventricular end-systolic dimension 4 cm • When mitral valve repair is deemed likely to be successful in asymptomatic patients with severe chronic MR and an LVEF 6 ...
Exercise Response in the heart
... The ability of the heart to stretch and increase the force of contraction is called the FrankStarling Law ...
... The ability of the heart to stretch and increase the force of contraction is called the FrankStarling Law ...
Heart Glossary – 20 Words You Should Know
... A device placed in the chest that monitors the heartbeat (also known as an automatic implantable cardioverter defibrillator—AICD). When the heart beats too fast, the ICD delivers a high-energy electrical impulse to restore a regular heart rhythm. ...
... A device placed in the chest that monitors the heartbeat (also known as an automatic implantable cardioverter defibrillator—AICD). When the heart beats too fast, the ICD delivers a high-energy electrical impulse to restore a regular heart rhythm. ...
Corporate Overview and Technology Summary
... – A novel cardiac support system, with unique advantages in providing circulatory support and recovery in patients with acute heart failure – Revenue potential: approximately $4 Billion per annum – Time to clinical trials in humans: approximately 15 months – Time to market: approximately 24 months – ...
... – A novel cardiac support system, with unique advantages in providing circulatory support and recovery in patients with acute heart failure – Revenue potential: approximately $4 Billion per annum – Time to clinical trials in humans: approximately 15 months – Time to market: approximately 24 months – ...
a case series of 10 patients
... major setbacks with regard to short-term effects, eg tachyphylaxis (4), and especially to long-term prognosis (5,6). Levosimendan acts through direct binding with troponin-C, thereby increasing the affinity of troponin-C for calcium in calcium dependent manner causing enhanced actin-myosin cross-bri ...
... major setbacks with regard to short-term effects, eg tachyphylaxis (4), and especially to long-term prognosis (5,6). Levosimendan acts through direct binding with troponin-C, thereby increasing the affinity of troponin-C for calcium in calcium dependent manner causing enhanced actin-myosin cross-bri ...
Echocardiographic assessment of diastolic function
... Assessment of regional myocardial function could be simply divided into systolic and diastolic function. Conventional assessment of cardiac function mainly focuses on global contractile and relaxation function. Tissue Doppler imaging (TDI) has a distinctive advantage where regional function can be e ...
... Assessment of regional myocardial function could be simply divided into systolic and diastolic function. Conventional assessment of cardiac function mainly focuses on global contractile and relaxation function. Tissue Doppler imaging (TDI) has a distinctive advantage where regional function can be e ...
Sudden Death in Young Athletes (3.20.11)
... Sudden death in young athletes There have been a number of recent tragic stories about high school and collegeaged ostensibly healthy youths dying unexpectedly after competing in physical activities. Many may wonder why this happens, and whether it is preventable. Common childhood illnesses such as ...
... Sudden death in young athletes There have been a number of recent tragic stories about high school and collegeaged ostensibly healthy youths dying unexpectedly after competing in physical activities. Many may wonder why this happens, and whether it is preventable. Common childhood illnesses such as ...
FORM
... 9) If the P-Q Segment of an ECG was longer than normal, you would be observing a ___________heart block. a) First degree b) Second degree c) Third degree d) Sinus rhythm e) Ectopic foci 10) Which have the fastest rate of conduction (about 3 meters/second) in the heart? a) Atrial myocytes b) AV Node ...
... 9) If the P-Q Segment of an ECG was longer than normal, you would be observing a ___________heart block. a) First degree b) Second degree c) Third degree d) Sinus rhythm e) Ectopic foci 10) Which have the fastest rate of conduction (about 3 meters/second) in the heart? a) Atrial myocytes b) AV Node ...
Atrial Fibrillation part 1
... many categories. However, they all have one common ground where the heart is in stress. Any type of illness can stress the heart enough to manifest its rhythm in A-Fib depending on the innate threshold of the heart. The more damage or disease the heart is in its structure, there is more chance or lo ...
... many categories. However, they all have one common ground where the heart is in stress. Any type of illness can stress the heart enough to manifest its rhythm in A-Fib depending on the innate threshold of the heart. The more damage or disease the heart is in its structure, there is more chance or lo ...
Introduction to Clinical Electrocardiography
... The heart is an electrical organ, and its activity can be measured noninvasively Wealth of information related to: ...
... The heart is an electrical organ, and its activity can be measured noninvasively Wealth of information related to: ...
Introduction to Clinical Electrocardiography
... The heart is an electrical organ, and its activity can be measured noninvasively Wealth of information related to: ...
... The heart is an electrical organ, and its activity can be measured noninvasively Wealth of information related to: ...
Measure #198 (NQF 0079): Heart Failure: Left Ventricular Ejection
... Evaluation of LVEF in patients with heart failure provides important information that is required to appropriately direct treatment. Several pharmacologic therapies have demonstrated efficacy in slowing disease progression and improving outcomes in patients with left ventricular systolic dysfunction ...
... Evaluation of LVEF in patients with heart failure provides important information that is required to appropriately direct treatment. Several pharmacologic therapies have demonstrated efficacy in slowing disease progression and improving outcomes in patients with left ventricular systolic dysfunction ...
Electrocardiography www.AssignmentPoint.com
... potential is then measured from twelve different angles ("leads") and is recorded over a period of time (usually 10 seconds). In this way, the overall magnitude and direction of the heart's electrical depolarization is captured at each moment throughout the cardiac cycle. The graph of voltage versus ...
... potential is then measured from twelve different angles ("leads") and is recorded over a period of time (usually 10 seconds). In this way, the overall magnitude and direction of the heart's electrical depolarization is captured at each moment throughout the cardiac cycle. The graph of voltage versus ...
Pacific Medical Systems Limited
... impaired cardiac output (CO), and increased morbidity and mortality. Doppler ultrasound is a reliable and reproducible method of measuring CO, and is routinely used to determine the severity of cardiac failure. Intractable cardiac failure may require cardiac transplantation for the prolongation of l ...
... impaired cardiac output (CO), and increased morbidity and mortality. Doppler ultrasound is a reliable and reproducible method of measuring CO, and is routinely used to determine the severity of cardiac failure. Intractable cardiac failure may require cardiac transplantation for the prolongation of l ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.